Company / Working Capital
Fulcrum Therapeutics, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$344.4M
FY2025
5-year range
$190.8M / $344.4M
FY2021-FY2025
Trend
+44.2%
vs FY2024
Sector context
#125 of 213
Health Care
What the data says
At $344M, Fulcrum Therapeutics, Inc.'s working capital ranks #125 of 213 in the Health Care sector. Working Capital has increased for 3 consecutive years, from $191M in FY2022 to $344M in FY2025.
Based on SEC 10-K filings.
$344M in FY2025 with a 5-year CAGR of +30.0%.
Improved from $229M to $344M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +21.8%
- 5-Year CAGR
- +30.0%
- 10-Year CAGR
- -
Sector benchmark
#125 of 213 in Health CareTop 59% of 213This company $344.4M Sector average $934.6M
▼
-63.1% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +30.0%, indicating consistent growth.
- In FY2025, working capital increased 44.2% year-over-year.
- Ranks #125 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $344.4M | +44.2% |
| FY2024 | $238.9M | +4.5% |
| FY2023 | $228.5M | +19.8% |
| FY2022 | $190.8M | -7.7% |
| FY2021 | $206.8M | +122.9% |
| FY2020 | $92.8M | +5.5% |
| FY2019 | $87.9M | +25.9% |
| FY2018 | $69.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026